0
Annual Meeting
Industry-Supported Symposia Cover Gamut
Psychiatric News
Volume 43 Number 7 page 31-31

Industry-supported symposia (ISS) are part of the scientific program of APA's annual meeting and are accredited for Category 1 CME credit. These symposia are submitted by APA members and are peer reviewed and selected by the Scientific Program Committee. They are supported by educational grants from pharmaceutical and medical-equipment companies and follow all standards and guidelines for commercial support set forth by the Accreditation Council for Continuing Medical Education.

As part of the APA screening process, the syllabi for the ISS presentations are peer reviewed for balance in advance by APA member volunteers. Feedback is given to presenters to change slides that are seen as biased toward a medication or treatment. Moreover, seating for meeting participants who do not wish to partake of pre-symposia meals are available, along with handouts.

All ISS are evaluated by participants and resident monitors for balance and quality. These evaluations are reviewed by the Scientific Program Committee and the Committee on Commercial Support.

All ISS are available as Webcasts after the meeting at no charge. They can be accessed at the Annual Meeting Online section of APA's Web site at<www.psych.org> under "Education and Career Development." Symposia handouts are also posted.

Below are the ISS that will be offered at APA's 2008 annual meeting. The schedule was not available at the time Psychiatric News produced its annual meeting issue (February 1). Because of possible scheduling changes, registrants are advised to check the program book on site at the meeting.

+

+

12:30 p.m.

+

ISS 1

Psychiatric Issues in Women Through the Adult Life-Cycle

Ballroom A/B, Level 3, Convention Center

Supporter: Wyeth Pharmaceuticals

+

ISS 2

Comprehensive Care for the Long-Term Patient With Schizophrenia: Treating the Whole Patient

Grand Ballroom, Ballroom Level, Renaissance

Supporter: Pfizer Inc.

+

ISS 3

Recent Advances in Alzheimer's Disease: Expert Opinions on Current and Emerging Theories

Independence Ballroom,Level 5B, Grand Hyatt

Supporter: Forest Laboratories Inc.

+

6:30 p.m.

+

ISS 4

Fibromyalgia: Diagnostic Advances and Emerging Pharmacologic Therapies for a Complex, Multidimensional Disorder

Ballroom A/B, Level 3, Convention Center

Supporter: Eli Lilly and Company

+

ISS 5

Addressing Unmet Clinical Needs in Severe Depression: Translating the Latest Findings

Grand Ballroom, Ballroom Level, Renaissance

Supporter: Sanofi-Aventis

+

ISS 6

Pediatric and Adolescent ADHD: Back to the Basics

Independence Ballroom, Level 5B, Grand Hyatt

Supporter: Abbott Laboratories

+

+

8 a.m.

+

ISS 7

Treating Patients Early: Updates on the Controversy

Ballroom A/B, Level 3, Convention Center

Supporter: AstraZeneca Pharmaceuticals

+

ISS 8

Advances in Neuroimaging and Genetics in ADHD

Grand Ballroom, Ballroom Level, Renaissance

Supporter: McNeil Pediatrics/Ortho-McNeil Janssen Scientific Affairs, LLC.

+

ISS 9

Recent Advances in the Diagnosis and Treatment of Fibromyalgia

Independence Ballroom, Level 5B, Grand Hyatt

Supporter: Pfizer Inc.

+

1:30 p.m.

+

ISS 10

Unlocking the Combination: Moving Toward a Better Understanding of Major Depressive Disorder

Ballroom A/B, Level 3, Convention Center

Supporter: Wyeth Pharmaceuticals

+

ISS 11

Genetics in Psychiatry: Opportunities and Obstacles in Schizophrenia

Grand Ballroom, Ballroom Level, Renaissance

Supporter: Vanda Pharmaceuticals

+

ISS 12

Treatment of Children and Adolescents With Psychiatric Disorders: The Rising Use of Antipsychotics

Independence Ballroom, Grand Hyatt Hotel

Supporter: Bristol-Myers Squibb Company and Otsuka America Pharmaceuticals

+

7 p.m.

+

ISS 13

Tangled Up in Blue: Optimizing Treatment of Depression in the Presence of Comorbidities

Ballroom A/B, Level 3, Convention Center

Supporter: Eli Lilly and Company

+

ISS 14

Mood Disturbance in Younger and Mid-Life Women: Defining Treatment Strategies

Grand Ballroom, Ballroom Level, Renaissance

Supporter: Forest Laboratories, Inc.

+

ISS 15

Using a Chronic Disease Model When Managing Patients With Severe Mental Illness

Independence Ballroom, Level 5B, Grand Hyatt

Supporter: Eli Lilly and Company

+

+

7 a.m.

+

ISS 16

Are Cognition, Sleep and Wake Disorders Caused by too Much Arousal, too Little Arousal or Both?

Ballroom A/B, Level 3, Convention Center

Supporter: Takeda Pharmaceuticals

+

ISS 17

Understanding Bipolar Disorder: Quality and Clinical Conundrums

Grand Ballroom, Ballroom Level, Renaissance

Supporter: Pfizer Inc.

+

ISS 18

Genetics, Brain Imaging, and Pharmacology: Clinical Implications for Therapeutic Choices in Schizophrenia and Bipolar Disorder

Independence Ballroom A-E, Level 5B, Grand Hyatt

Supporter: Organon Pharmaceuticals USA Inc.

+

+

7 p.m.

+

ISS 19

Is Recovery Attainable in Schizophrenia? Biologic, Pharmacologic, and Psychologic Perspectives

Ballroom A/B, Level 3, Convention Center

Supporter: AstraZeneca Pharmaceuticals

+

ISS 20

Novel and Current Antidepressants: State-of-the-Art Management of Depression

Grand Ballroom, Ballroom Level, Renaissance

Supporter: Novartis Pharmaceuticals Corporation

+

ISS 21

Sleep and Sleep Disorders Across the Life Cycle: What Psychiatrists Need to Know

Independence Ballroom, Level 5B, Grand Hyatt

Supporter: Sepracor, Inc.

+

+

7 p.m.

+

ISS 22

Organizing the Evidence: Obsessive Compulsive Related Disorders: New Perspectives Toward DSM-V

Ballroom A/B, Level 3, Convention Center

Supporter: Jazz Pharmaceuticals, Inc.

+

ISS 23

Understanding the Endocannabinoid System: Key Links Between Mind, Body, and Neuropsychiatry

Grand Ballroom, Ballroom Level, Renaissance

Supporter: Sanofi-Aventis

Schizophrenia: The Complexity of Real-World Care

Independence Ballroom A-E, Level 5B, Grand Hyatt

Supporter: Janssen Pharmaceutica and Research

+

+

7 p.m.

+

ISS 26

Novel Perspectives Towards a Better Understanding of Major Depressive Disorder

Ballroom A/B, Level 3, Convention Center

Supporter: Bristol-Myers Squibb Company and Otsuka America Pharmaceuticals

+

ISS 27

Individualizing Treatment Plans for Total Health in Patients With Bipolar Disorder

Ballroom C, Level 3, Convention Center

Supporter: Organon Pharmaceuticals USA Inc.

+

ISS 28

Advancing Science and Practice in the Management of ADHD From Child to Adult: An Interactive Case Presentation

Grand Ballroom, Ballroom Level, Renaissance

Supporter: Shire US, Inc.

+

ISS 29

Beyond Pain to "Fibrofog" and Sleep Impairments: Implications for Neurocircuitry and Treatments in Fibromyalgia

Independence Ballroom A-E, Level 5B, Grand Hyatt

Supporter: Pfizer Inc.

Interactive Graphics

Video

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles
Articles